Cartesian Therapeutics

Cartesian Therapeutics Goodwill

The Goodwill of Cartesian Therapeutics (RNAC) as of Oct 18, 2026 is 48.16 M USD. In the previous year, Goodwill was 48.16 M USD — a change of 0.00% (lower).

Goodwill

48.16 MUSD

YoY

0.00%

Last updated:

Goodwill of Cartesian Therapeutics is 2025 48.16 M USD. Goodwill of Cartesian Therapeutics was 2024 48.16 M USD. It decreases by 0.00% lower compared to the previous year.

The Cartesian Therapeutics Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
48.16 M USD
Jan 1, 2024
48.16 M USD
Jan 1, 2025
48.16 M USD
The Cartesian Therapeutics Goodwill history
YEARGoodwillYoY
48.16 MUSD0.00%
48.16 MUSD0.00%
48.16 MUSD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cartesian Therapeutics Stock analysis

What does Cartesian Therapeutics do? Cartesian Therapeutics Inc, trading under the ticker RNAC, is a biotechnology company based in Watertown, United States. The company has 75 employees and went public via an IPO on June 22, 2016. Cartesian Therapeutics operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is https://selectabio.com/. Cartesian Therapeutics focuses on developing therapeutic solutions, though specific product names or clinical stage details are not provided in the available information. The company's headquarters are located in Watertown, and it is engaged in research and development activities typical of a biopharmaceutical firm. Cartesian Therapeutics is identified by its ISIN number US8162123025. The company's activities are centered around advancing biotechnology for healthcare applications, with a focus on innovative therapeutic approaches. The company's operational scope and specific research areas are not detailed beyond the general biotechnology sector focus. Cartesian Therapeutics is a clinical-stage biopharmaceutical company, though the exact stage of clinical development for any specific therapy is not specified in the provided data. The company's website serves as a primary source of information for further details on its operations and developments. Cartesian Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cartesian Therapeutics stock

Goodwill of Cartesian Therapeutics is 48.16 M USD in 2025.

Goodwill of Cartesian Therapeutics changed from 48.16 M USD to 48.16 M USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Cartesian Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Cartesian Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cartesian Therapeutics

All Key Metrics — Cartesian Therapeutics